Medical Dialogues
  • Dermatology
Login Register
This site is intended for healthcare professionals only
Login Register
  • MD Brand Connect
  • Vaccine Hub
  • MDTV
    • Breaking News
    • Medical News Today
    • Health News Today
    • Latest
    • Journal Club
    • Medico Legal Update
    • Latest Webinars
    • MD Shorts
    • Health Dialogues
  • Fact Check
  • Health Dialogues
Medical Dialogues
  • Medical News & Guidelines
      • Anesthesiology
      • Cardiology and CTVS
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endocrinology
      • ENT
      • Gastroenterology
      • Medicine
      • Nephrology
      • Neurology
      • Obstretics-Gynaecology
      • Oncology
      • Ophthalmology
      • Orthopaedics
      • Pediatrics-Neonatology
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
      • Laboratory Medicine
      • Diet
      • Nursing
      • Paramedical
      • Physiotherapy
  • Health news
      • Doctor News
      • Government Policies
      • Hospital & Diagnostics
      • International Health News
      • Medical Organization News
      • Medico Legal News
      • NBE News
      • NMC News
  • Fact Check
      • Bone Health Fact Check
      • Brain Health Fact Check
      • Cancer Related Fact Check
      • Child Care Fact Check
      • Dental and oral health fact check
      • Diabetes and metabolic health fact check
      • Diet and Nutrition Fact Check
      • Eye and ENT Care Fact Check
      • Fitness fact check
      • Gut health fact check
      • Heart health fact check
      • Kidney health fact check
      • Medical education fact check
      • Men's health fact check
      • Respiratory fact check
      • Skin and hair care fact check
      • Vaccine and Immunization fact check
      • Women's health fact check
  • AYUSH
    • Ayurveda
    • Homeopathy
    • Siddha
    • Unani
    • Yoga
  • State News
      • Andaman and Nicobar Islands
      • Andhra Pradesh
      • Arunachal Pradesh
      • Assam
      • Bihar
      • Chandigarh
      • Chattisgarh
      • Dadra and Nagar Haveli
      • Daman and Diu
      • Delhi
      • Goa
      • Gujarat
      • Haryana
      • Himachal Pradesh
      • Jammu & Kashmir
      • Jharkhand
      • Karnataka
      • Kerala
      • Ladakh
      • Lakshadweep
      • Madhya Pradesh
      • Maharashtra
      • Manipur
      • Meghalaya
      • Mizoram
      • Nagaland
      • Odisha
      • Puducherry
      • Punjab
      • Rajasthan
      • Sikkim
      • Tamil Nadu
      • Telangana
      • Tripura
      • Uttar Pradesh
      • Uttrakhand
      • West Bengal
  • Medical Education
      • Ayush Education News
      • Dentistry Education News
      • Medical Admission News
      • Medical Colleges News
      • Medical Courses News
      • Medical Universities News
      • Nursing education News
      • Paramedical Education News
      • Study Abroad
  • Industry
      • Health Investment News
      • Health Startup News
      • Medical Devices News
      • Pharma News
      • Pharmacy Education News
      • Industry Perspective
  • MDTV
      • Health Dialogues MDTV
      • Health News today MDTV
      • Latest Videos MDTV
      • Latest Webinars MDTV
      • MD shorts MDTV
      • Medical News Today MDTV
      • Medico Legal Update MDTV
      • Top Videos MDTV
      • Health Perspectives MDTV
      • Journal Club MDTV
      • Medical Dialogues Show
This site is intended for healthcare professionals only
LoginRegister
Medical Dialogues
LoginRegister
  • Home
  • Medical news & Guidelines
    • Anesthesiology
    • Cardiology and CTVS
    • Critical Care
    • Dentistry
    • Dermatology
    • Diabetes and Endocrinology
    • ENT
    • Gastroenterology
    • Medicine
    • Nephrology
    • Neurology
    • Obstretics-Gynaecology
    • Oncology
    • Ophthalmology
    • Orthopaedics
    • Pediatrics-Neonatology
    • Psychiatry
    • Pulmonology
    • Radiology
    • Surgery
    • Urology
    • Laboratory Medicine
    • Diet
    • Nursing
    • Paramedical
    • Physiotherapy
  • Health news
    • Doctor News
    • Government Policies
    • Hospital & Diagnostics
    • International Health News
    • Medical Organization News
    • Medico Legal News
    • NBE News
    • NMC News
  • Fact Check
    • Bone Health Fact Check
    • Brain Health Fact Check
    • Cancer Related Fact Check
    • Child Care Fact Check
    • Dental and oral health fact check
    • Diabetes and metabolic health fact check
    • Diet and Nutrition Fact Check
    • Eye and ENT Care Fact Check
    • Fitness fact check
    • Gut health fact check
    • Heart health fact check
    • Kidney health fact check
    • Medical education fact check
    • Men's health fact check
    • Respiratory fact check
    • Skin and hair care fact check
    • Vaccine and Immunization fact check
    • Women's health fact check
  • AYUSH
    • Ayurveda
      • Ayurveda Giuidelines
      • Ayurveda News
    • Homeopathy
      • Homeopathy Guidelines
      • Homeopathy News
    • Siddha
      • Siddha Guidelines
      • Siddha News
    • Unani
      • Unani Guidelines
      • Unani News
    • Yoga
      • Yoga Guidelines
      • Yoga News
  • State News
    • Andaman and Nicobar Islands
    • Andhra Pradesh
    • Arunachal Pradesh
    • Assam
    • Bihar
    • Chandigarh
    • Chattisgarh
    • Dadra and Nagar Haveli
    • Daman and Diu
    • Delhi
    • Goa
    • Gujarat
    • Haryana
    • Himachal Pradesh
    • Jammu & Kashmir
    • Jharkhand
    • Karnataka
    • Kerala
    • Ladakh
    • Lakshadweep
    • Madhya Pradesh
    • Maharashtra
    • Manipur
    • Meghalaya
    • Mizoram
    • Nagaland
    • Odisha
    • Puducherry
    • Punjab
    • Rajasthan
    • Sikkim
    • Tamil Nadu
    • Telangana
    • Tripura
    • Uttar Pradesh
    • Uttrakhand
    • West Bengal
  • Medical Education
    • Ayush Education News
    • Dentistry Education News
    • Medical Admission News
    • Medical Colleges News
    • Medical Courses News
    • Medical Universities News
    • Nursing education News
    • Paramedical Education News
    • Study Abroad
  • Industry
    • Health Investment News
    • Health Startup News
    • Medical Devices News
    • Pharma News
      • CDSCO (Central Drugs Standard Control Organisation) News
    • Pharmacy Education News
    • Industry Perspective
  • Home
  • News
  • Industry
  • Pharma News
  • Post-Patent Expiry...

Post-Patent Expiry Boom, Empagliflozin Sees Brand Flood, 147 Brands Launched: Pharmatrac

Farhat NasimWritten by Farhat Nasim Published On 2025-05-09T19:51:43+05:30  |  Updated On 9 May 2025 7:51 PM IST
Post-Patent Expiry Boom, Empagliflozin Sees Brand Flood, 147 Brands Launched: Pharmatrac
  • facebook
  • twitter
  • linkedin
  • whatsapp
  • Telegram
  • Email

Empagliflozin plain and its combination with Linagliptin currently account for about 80% of total sales in this Rs 745 crore market.

New Delhi: The Indian Pharmaceutical Market (IPM) registered a robust 7.8% growth in April 2025, largely fueled by price hikes, new product introductions, and growing momentum in anti-diabetic therapies. On an annual basis, the MAT (Moving Annual Total) growth stood at 8.3%, taking the overall market value to Rs 2,27,361 crore, as per the latest PharmaTrac report released by Pharmarack.

One of the most significant developments was the surge in activity in the Empagliflozin segment, following the drug's patent expiry. The total number of brands in this category rose from 86 to 147 in just a few months, as more than 37 companies entered the space. Although the overall value of the segment remained relatively flat with a 1% year-on-year decline, volume consumption jumped 10%, reflecting improved affordability and access. Empagliflozin plain and its combination with Linagliptin currently account for about 80% of total sales in this Rs 745 crore market, underlining strong physician and patient adoption amid intense post-patent competition.

Brands in Market Post Patent Loss (Empagliflozin Segment)

SubgroupMar 2025 - BrandsMar 2025 - CompaniesApr 2025 - BrandsApr 2025 - CompaniesLaunch Date
Empagliflozin22183632Oct-18
Empagliflozin + Linagliptin19144031Jun-18
Empagliflozin + Metformin21153729Jun-18
Empagliflozin + Linagliptin + Metformin3275Mar-25
Empagliflozin + Sitagliptin21152818Mar-25

Additionally, the report notes, “If one removes the overlap, there are close to 147 brands from 37 companies that have started featuring in the Empagliflozin Plain and Combinations market now. This number was 86 brands and 19 Companies in Mar 25.”

Meanwhile, the broader anti-diabetic category continued its strong showing, posting 7.7% year-on-year growth and crossing the Rs 20,800 crore mark. Within this space, insulin therapies alone contributed over Rs 4,400 crore, growing at 7%. Oral anti-diabetics still dominate with a 79% market share, but the insulin segment is gradually expanding, with domestic players gaining ground. Abbott (marketing Novo Nordisk insulin) maintained leadership with a 60% share, followed by Sanofi India, Lupin, and Eris Lifesciences. Notably, Indian entrants such as Cipla, USV, and Mankind posted aggressive year-on-year gains, with USV’s insulin portfolio soaring by 336% and Mankind’s growing by 66%.

In a related development, Eli Lilly’s Mounjaro (tirzepatide), a novel GLP-1/GIP dual agonist therapy for diabetes and obesity, is showing early signs of traction in the Indian market. Monthly sales climbed from Rs 1.42 crore in March to Rs 4.80 crore in April, with volumes jumping from 5,400 to 18,270 units. While the figures are still small in comparison to conventional insulins, the trend may signal growing prescriber interest in once-weekly anti-diabetic options, especially among urban consumers.

Among therapeutic segments, cardiac therapy led the market in value, touching Rs 30,483 crore with a 10.6% annual growth, followed closely by gastrointestinal therapies at Rs 27,612 crore. Neurology, dermatology, and anti-neoplastics all posted above 9% year-on-year growth, though April month growth across many therapies remained in the mid-to-high single digits. Importantly, volume growth continued to lag in most categories, indicating that recent expansion has been largely price-led.

On the corporate front, Sun Pharma retained its lead with Rs 18,863 crore in MAT sales, followed by Abbott and Mankind. Among the top-selling brands were Augmentin (Rs 820 Cr, GSK), Glycomet GP (Rs 806 Cr, USV), and Liv.52 (Rs 740 Cr, Himalaya). Insulin brand Mixtard also stood out with Rs 766 crore in annual sales.

Overall, the April snapshot suggests that the Indian pharmaceutical market continues to maintain its upward trajectory, aided by brand expansions, increasing chronic disease burden, and evolving treatment preferences. The spike in Empagliflozin competition post-patent and growing demand for next-gen therapies like Mounjaro point to a market that is becoming both more competitive and more innovation-driven.

ipm april 2025empagliflozin indiaempagliflozin patent expiryindian pharma market growthanti-diabetic drug marketmounjaro india launchpharmatrac report aprilinsulin market indiaabbottsun pharmamankind pharmausv growthpharma brand competitionLinagliptinmetforminSitagliptin
Farhat Nasim
Farhat Nasim

    Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

    Show Full Article
    Next Story

    Editorial

    Real-World Case study: Darbepoetin Alfa for Chemotherapy-Induced Anemia in Metastatic Breast Cancer - Dr Aditya Murali

    Real-World Case study: Darbepoetin Alfa for Chemotherapy-Induced Anemia in Metastatic Breast Cancer...

    Aspirin in Primary Prevention- When to Consider?

    Aspirin in Primary Prevention- When to Consider?

    Featured image representing medico legal

    What's the Role of Expert Opinion in Medical Negligence?

    7- Point Discharge Protocol for AECOPD: Time to Inculcate in Practice

    7- Point Discharge Protocol for AECOPD: Time to Inculcate in Practice

    Aspirin Use in Women Aged 40-50 with Diabetes and Hypertension: Identifying the Ideal Candidates

    Aspirin Use in Women Aged 40-50 with Diabetes and Hypertension: Identifying the Ideal Candidates

    View All

    Journal Club Today

    Real-World Case study: Darbepoetin Alfa for Chemotherapy-Induced Anemia in Metastatic Breast Cancer - Dr Aditya Murali

    Real-World Case study: Darbepoetin Alfa for Chemotherapy-Induced Anemia in Metastatic Breast Cancer...

    View All

    Health News Today

    Health Bulletin 09/ May/ 2025

    Health Bulletin 09/ May/ 2025

    View All
    © 2022 All Rights Reserved.
    Powered By: Hocalwire
    X
    We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok